Welcome to our dedicated page for Integra Lifesciences Hldgs Cp SEC filings (Ticker: IART), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integra LifeSciences’ filings rarely stop at simple balance sheets—they dive into FDA approvals, regenerative tissue compliance, and Codman Specialty Surgical revenue splits that can span 300 pages. Finding the section on wound-matrix recall costs or the exact R&D spend per neurosurgical implant is a challenge investors mention often.
Our platform answers that challenge. Stock Titan’s AI reads every 10-K, 10-Q, 8-K, and Form 4 the moment it hits EDGAR, then explains the impact in plain English. Want to see "Integra LifeSciences quarterly earnings report 10-Q filing" or compare “Integra LifeSciences annual report 10-K simplified” across years? It’s one click. Looking for "Integra LifeSciences insider trading Form 4 transactions"? Get real-time alerts the instant an executive buys or sells.
Here’s what you can do:
- Track "Integra LifeSciences executive stock transactions Form 4" and spot buying patterns before earnings calls.
- Read "Integra LifeSciences proxy statement executive compensation" without parsing legalese—our AI highlights pay vs. performance.
- Identify product-specific risks in "Integra LifeSciences 8-K material events explained," from manufacturing updates to distribution pauses.
- Use "understanding Integra LifeSciences SEC documents with AI" to compare Codman vs. Tissue Technologies margins over time.
- Dive into "Integra LifeSciences earnings report filing analysis" to gauge demand for regenerative tissue matrices.
Whether you need "Integra LifeSciences Form 4 insider transactions real-time" or a clear summary of the latest "Integra LifeSciences SEC filings explained simply," Stock Titan turns technical disclosures into actionable knowledge—so you can focus on surgical-device fundamentals, not footnotes.
Rubric Capital Management LP, an investment adviser headquartered in New York, and its managing member David Rosen jointly filed Amendment No. 2 to Schedule 13G on 07 July 2025 regarding their holdings in Ovid Therapeutics Inc. (OVID).
- Beneficial ownership: 478,533 common shares.
- Ownership percentage: 0.67 % of the 71,109,514 shares outstanding as of 19 May 2025 (per the issuer’s latest proxy).
- Voting & disposition rights: 0 shares sole voting/dispositive power; 478,533 shares shared voting and shared dispositive power.
- Reporting persons: Rubric Capital (investment adviser) and David Rosen (individual, control person).
- Filing trigger date: 30 June 2025; the position is now below the 5 % threshold, leading to a “Ownership of 5 percent or Less” disclosure.
- Certification: Securities held in the ordinary course and not for the purpose of influencing control.
The filing is informational, confirming a modest (<1 %) stake by Rubric Capital without indicating any intent to alter the company’s control or strategy.
Aviat Networks, Inc. (AVNW) has filed a Form 4 announcing that Erin Boase, Vice President – Legal Affairs, sold 5,634 shares of common stock on 07/03/2025. The transaction was coded “S” and executed under a Rule 10b5-1 trading plan, indicating it was pre-scheduled. The reported sale price was $25 per share, generating gross proceeds of about $140.9 thousand. After the disposition, Boase directly owns 22,290 shares of AVNW. No derivative securities transactions were disclosed, and no other insiders were involved in this filing.
The event represents a reduction of roughly 20% of Boase’s previously held position (calculated from the filing data). While insider selling can sometimes be viewed cautiously, the 10b5-1 plan mitigates concerns of opportunistic timing. The transaction is modest relative to Aviat Networks’ overall share count and does not alter corporate control.
Mueller Water Products, Inc. (MWA) Form 4 filing dated 07 July 2025 details a small open-market purchase by Director Brian C. Healy.
- Healy bought 1,110 common shares at a weighted average price of $24.74 per share.
- The transaction was executed under a Rule 10b5-1 trading plan adopted on 07 Feb 2025, indicating it was pre-arranged and not reactive to non-public information.
- Following the purchase, the director’s direct beneficial ownership rises to 15,730 shares.
- No derivative securities were involved and no dispositions were reported.
While the dollar value of the purchase (~$27,500) is modest relative to MWA’s market capitalization, insider buying—particularly by a board member—can be interpreted as a signal of confidence in the company’s outlook. Because the trade was executed pursuant to a preset plan, it reduces concerns about information asymmetry but still represents incremental insider alignment with shareholder interests.
Form 4 filing summary – KeyCorp (KEY), 07/01/2025: Director Barbara R. Snyder converted 35,955 deferred shares (transaction code M) into an equal number of common shares. The conversion increased her directly held common-share position to 71,632 shares. No open-market purchase or sale price was reported because the shares derive from KeyCorp’s Directors’ Deferred Share Sub-Plan, where each deferred share is economically equivalent to a common share. Following the transaction, Snyder still holds 177,901 deferred shares that remain subject to the plan. The filing also notes that direct ownership totals include roughly 175 common shares obtained through the June 2025 dividend-reinvestment program, and deferred-share holdings include about 2,765 dividend-equivalent units accrued during the same period. As there was no disposition of shares and the transaction merely settles a long-standing equity award, the impact on KeyCorp’s public float and insider sentiment is modest.